人福医药
(600079)
| 流通市值：335.33亿 | | | 总市值：354.68亿 |
| 流通股本：15.43亿 | | | 总股本：16.32亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 19,143,374,654.64 | 12,861,283,334.71 | 6,367,371,531.88 | 24,524,740,572.69 |
| 营业收入 | 19,143,374,654.64 | 12,861,283,334.71 | 6,367,371,531.88 | 24,524,740,572.69 |
| 二、营业总成本 | 16,644,223,107.45 | 11,126,432,608.62 | 5,584,162,042.55 | 21,417,059,137.08 |
| 营业成本 | 10,192,306,440.83 | 6,844,655,355.35 | 3,412,875,696.1 | 13,290,991,557.35 |
| 税金及附加 | 160,955,318.04 | 104,285,980.11 | 51,186,293.93 | 191,747,055.27 |
| 销售费用 | 3,477,070,885.85 | 2,380,822,325.92 | 1,203,802,252.65 | 4,397,798,774.97 |
| 管理费用 | 1,393,358,750.94 | 935,874,304.57 | 486,502,809.84 | 1,770,060,888.32 |
| 研发费用 | 1,093,259,846.85 | 705,834,992.85 | 349,340,705.03 | 1,461,942,028.6 |
| 财务费用 | 327,271,864.94 | 154,959,649.82 | 80,454,285 | 304,518,832.57 |
| 其中:利息费用 | 269,916,260.54 | 178,694,372.28 | 85,200,005.56 | 354,141,696.04 |
| 其中:利息收入 | 40,151,700.63 | 33,601,816.2 | 13,685,685.29 | 58,771,065.02 |
| 加:公允价值变动收益 | -7,258,698.89 | -5,660,932.78 | -6,536,363.61 | 136,854,734.94 |
| 加:投资收益 | 80,482,162.86 | 28,708,651.29 | 16,870,550.16 | 206,785,478.83 |
| 资产处置收益 | -3,113,228.19 | -532,848.97 | 513,191.27 | -1,084,924.95 |
| 资产减值损失(新) | -4,248,993.13 | -4,036,730.68 | 986,604.69 | -61,407,302.82 |
| 信用减值损失(新) | -48,798,603.11 | -30,068,997.03 | -16,877,771.55 | -147,357,909.38 |
| 其他收益 | 139,499,178.04 | 96,923,675.5 | 44,347,913.76 | 205,702,658.11 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,655,713,364.77 | 1,820,183,543.42 | 822,513,614.05 | 3,447,174,170.34 |
| 加:营业外收入 | 6,481,674.13 | 1,265,964.16 | 627,700.46 | 8,284,582.89 |
| 减:营业外支出 | 73,211,831.95 | 45,981,154.96 | 13,616,262.67 | 71,629,921.26 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,588,983,206.95 | 1,775,468,352.62 | 809,525,051.84 | 3,383,828,831.97 |
| 减:所得税费用 | 481,602,428.62 | 319,838,000.16 | 161,336,256.36 | 568,563,020.27 |
| 六、净利润 | 2,107,380,778.33 | 1,455,630,352.46 | 648,188,795.48 | 2,815,265,811.7 |
| 持续经营净利润 | 2,107,380,778.33 | 1,455,630,352.46 | 648,188,795.48 | 2,815,265,811.7 |
| 归属于母公司股东的净利润 | 1,589,694,392.14 | 1,111,094,974.15 | 486,392,045.37 | 2,134,484,688.96 |
| 少数股东损益 | 517,686,386.19 | 344,535,378.31 | 161,796,750.11 | 680,781,122.74 |
| (一)基本每股收益 | 0.98 | 0.68 | 0.3 | 1.32 |
| (二)稀释每股收益 | 0.97 | 0.68 | 0.3 | 1.31 |
| 八、其他综合收益 | 121,805,252.07 | -133,563,877.3 | -35,025,830.5 | 32,370,529.47 |
| 归属于母公司股东的其他综合收益 | 131,483,333.54 | -124,962,560.43 | -31,008,824.54 | 36,319,681.82 |
| 九、综合收益总额 | 2,229,186,030.4 | 1,322,066,475.16 | 613,162,964.98 | 2,847,636,341.17 |
| 归属于母公司股东的综合收益总额 | 1,721,177,725.68 | 986,132,413.72 | 455,383,220.83 | 2,170,804,370.78 |
| 归属于少数股东的综合收益总额 | 508,008,304.72 | 335,934,061.44 | 157,779,744.15 | 676,831,970.39 |
| 公告日期 | 2024-10-30 | 2024-07-27 | 2024-04-30 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |